Thoracic Fluid Content by Bioimpedance-based Starling System
Launched by BICETRE HOSPITAL · Jan 6, 2023
Trial Information
Current as of June 04, 2025
Completed
Keywords
ClinConnect Summary
The Starling system is a completely non-invasive hemodynamic monitoring technique. It measures cardiac output through bioreactance. It also measures the mean transthoracic electric impedance (Z0) from which the thoracic fluid content (TFC) can be derived. The TFC is the only other variable that is provided by the system besides cardiac output and that is not inferred from it. The TFC is supposed to reflect the total content of fluid in the thorax and may include two of the variables that are commonly used for hemodynamic monitoring: the extravascular lung water (EVLW), which is the volume o...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 y.o.
- • Hospitalization in an ICU
- • Monitoring by transpulmonary thermodilution already in place
- • Decision by clinicians in charge to perform volume expansion by saline or fluid removal by diuretics infusion and/or ultrafiltration ("Fluid" group)
- • Or presence of Acute Respiratory Distress Syndrome according to the Berlin definition ("ARDS" group)
- Exclusion Criteria:
- • Refusal to join the study
- • In "Fluid" group, circulatory failure whose treatment cannot be postponed for ≥5 minutes (time required for the installation of Starling system).
- • Impossibility to paste bioreactance electrodes properly in the skin of the thorax.
About Bicetre Hospital
Bicetre Hospital, a renowned healthcare institution located in France, is dedicated to advancing medical research and patient care through innovative clinical trials. As a key player in the clinical research landscape, the hospital leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous studies across various therapeutic areas. With a commitment to ethical standards and patient safety, Bicetre Hospital fosters collaboration among healthcare professionals, researchers, and pharmaceutical partners to drive the development of new treatments and improve health outcomes for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Le Kremlin Bicêtre, île De France, France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials